BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 35122210)

  • 1. A review of the safety and efficacy of current COVID-19 vaccines.
    Huang Z; Su Y; Zhang T; Xia N
    Front Med; 2022 Feb; 16(1):39-55. PubMed ID: 35122210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis.
    Liu Q; Qin C; Liu M; Liu J
    Infect Dis Poverty; 2021 Nov; 10(1):132. PubMed ID: 34776011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Vaccination contre le SARS-CoV-2, le Graal ?].
    Binh Luong Nguyen L; Lachâtre M; Launay O
    Rev Prat; 2022 May; 72(5):517-522. PubMed ID: 35899638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic.
    Shao Y; Wu Y; Feng Y; Xu W; Xiong F; Zhang X
    Front Med; 2022 Apr; 16(2):185-195. PubMed ID: 35226300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects.
    Zhang Z; Shen Q; Chang H
    Front Immunol; 2022; 13():843928. PubMed ID: 35572592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The way of SARS-CoV-2 vaccine development: success and challenges.
    Dong Y; Dai T; Wang B; Zhang L; Zeng LH; Huang J; Yan H; Zhang L; Zhou F
    Signal Transduct Target Ther; 2021 Nov; 6(1):387. PubMed ID: 34753918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive analysis of the efficacy and safety of COVID-19 vaccines.
    Cai C; Peng Y; Shen E; Huang Q; Chen Y; Liu P; Guo C; Feng Z; Gao L; Zhang X; Gao Y; Liu Y; Han Y; Zeng S; Shen H
    Mol Ther; 2021 Sep; 29(9):2794-2805. PubMed ID: 34365034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms.
    Jafari A; Danesh Pouya F; Niknam Z; Abdollahpour-Alitappeh M; Rezaei-Tavirani M; Rasmi Y
    Mol Biol Rep; 2022 Jun; 49(6):4943-4957. PubMed ID: 35235159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations.
    He Q; Mao Q; Zhang J; Bian L; Gao F; Wang J; Xu M; Liang Z
    Front Immunol; 2021; 12():669339. PubMed ID: 33912196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity, efficacy and safety of COVID-19 vaccines: an update of data published by 31 December 2021.
    Xu K; Fan C; Han Y; Dai L; Gao GF
    Int Immunol; 2022 Dec; 34(12):595-607. PubMed ID: 35778913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [SARS-CoV-2 vaccines].
    Benfield TL; Helweg-Larsen J
    Ugeskr Laeger; 2021 Mar; 183(10):. PubMed ID: 33734065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies and safety considerations of booster vaccination in COVID-19.
    Meng H; Mao J; Ye Q
    Bosn J Basic Med Sci; 2022 Jun; 22(3):366-373. PubMed ID: 35366790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 variants, immune escape, and countermeasures.
    Zhang Y; Zhang H; Zhang W
    Front Med; 2022 Apr; 16(2):196-207. PubMed ID: 35253097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges.
    Malik JA; Ahmed S; Mir A; Shinde M; Bender O; Alshammari F; Ansari M; Anwar S
    J Infect Public Health; 2022 Feb; 15(2):228-240. PubMed ID: 35042059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A COVID-19 vaccine-dare to dream.
    Phillis A
    Br J Community Nurs; 2020 Dec; 25(12):2-7. PubMed ID: 33275510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.